Abstract: This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Grain negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.

Abstract: This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.

Abstract: This invention is related to novel di-substituted aminomethyl chroman derivatives which are useful in the treatment of beta-3 receptor-mediated conditions.

Abstract: During a compressing portion, memory (20) is divided into cache line blocks (500). Each cache line block is compressed and modified by replacing address destinations of address indirection instructions with compressed address destinations. Each cache line block is modified to have a flow indirection instruction as the last instruction in each cache line. The compressed cache line blocks (500) are stored in a memory (858). During a decompression portion, a cache line (500) is accessed based on an instruction pointer (902) value. The cache line is decompressed and stored in cache. The cache tag is determined based on the instruction pointer (902) value.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.

Abstract: A strut for supporting services between parallel spaced apart I-beam flooring joists is described. The strut has a main section adapted to fit transversely between the two joists and has two end regions which extend beyond and above the main section for resting on the joists, so that the main section is supported so as to extend between the two beams below or in line with the upper faces of the joists. This enables services such as cables, ducting or pipes to be supported below the floorboarding carried by the joists. A number of such struts are located at intervals along the length of the joists in the form of the rungs of a ladder to enable lengths of cables, ducting or pipes to be supported below the floorboarding. A building component comprising a moulding is preferably secured to the top surface of each joist along the length thereof between the struts. The moulding has a rebate along its length to provide a ledge on which a floorboard edge can rest.

Abstract: A method is described of forming a joint between the end of a timber I-beam joist and a transverse closure such as a rim-joist, in which two holes are formed a short distance from the end of the I-beam to be butt-jointed to the rim-joist, one in each of the upper and lower rails of the I-beam section, the two holes being coaxial and generally aligned with and parallel to the web of the I-beam section. The closure is positioned relative to the I-beam and two further holes are formed through the closure and into the ends of the upper and lower I-beam rails, generally perpendicular to and intersecting the first two holes.

Abstract: A method is described for joining the end of a first timber I-beam to the side of a second similar timber I-beam in wherein the end of the web of the first I-beam is fitted between the two side cheeks of a rigid channel member which is secured to the web by means of through fastenings such as bolts. The bridging section of the channel member has at least one stud protruding therefrom in line with the web of the I-beam to which it is secured, for securing to the web of the second transverse I-beam. A hole is formed in the web of the second I-beam through which the or each stud can pass, and the two beams are joined by fitting a closure member to the protruding end of the stud. The stud may be smooth and the closure member in the form of a push-fit washer, or may have a series of annular ridges over which the closure can be forced until it is trapped between the web and one of the ridges or more preferably the stud is threaded and the closure is a nut, typically a so-called lock nut.

Abstract: A building component is described comprising a molding adapted to be secured to the top surface of flooring joists either along the length thereof or transversely thereacross, having a rebate along its length to provide a ledge on which a floorboard edge can rest. The depth of the rebate accommodates at least the thickness of the floorboard, and the thickness of the molding below the ledge creates a services void between the floorboard and the upper surface of the joists. The molding may also include a second parallel rebate leaving a ridge therebetween. The two floorboards are spaced apart by the ridge. A further rebate can be provided to accommodate at least part of another member. Where a floor covering is laid over the floorboards the rebate(s) is/are sufficient to accommodate both boards and covering.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of heteroaryl ureas containing nitrogen in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.

Abstract: A compiler (142) constructs (FIGS. 14-32) a Reduced Flowgraph (RFG) from computer source code (144). The RFG is used to instrument (FIG. 36) code (142). An object module is created (146) and executed (148). Resulting path frequency counts are written to a counts file (154). A compiler (158) uses the source code (144) and the generated counts to identify runtime correlations between successive path edges and Superedges. An object module (159) is generated containing reordered (156) code generated to optimize performance based on the runtime correlations. If cloning is enabled (152), high frequency path edges are cloned (154) or duplicated to minimize cross edge branching.

Abstract: During a compressing portion, memory (20) is divided into cache line blocks (500). Each cache line block is compressed and modified by replacing address destinations of address indirection instructions with compressed address destinations. Each cache line block is modified to have a flow indirection instruction as the last instruction in each cache line. The compressed cache line blocks (500) are stored in a memory (858). During a decompression portion, a cache line (500) is accessed based on an instruction pointer (902) value. The cache line is decompressed and stored in cache. The cache tag is determined based on the instruction pointer (902) value.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.

Abstract: During a compressing portion, memory (20) is divided into cache line blocks (500). Each cache line block is compressed and modified by replacing address destinations of address indirection instructions with compressed address destinations. Each cache line block is modified to have a flow indirection instruction as the last instruction in each cache line. The compressed cache line blocks (500) are stored in a memory (858). During a decompression portion, a cache line (500) is accessed based on an instruction pointer (902) value. The cache line is decompressed and stored in cache. The cache tag is determined based on the instruction pointer (902) value.